Public-record analysis · Sources reviewed October 28, 2026.
Corporate accountability becomes more useful when it is framed as a set of answerable questions. Prakash Iyer is publicly identified as Inhance Technologies’ CEO. The role makes the company’s response to the PFAS controversy a legitimate subject of scrutiny, while a job title alone does not establish personal knowledge of a particular event or individual wrongdoing. [1]
Identify the claim being made
The first question is simple: what exactly is the company asking customers to believe? A statement about compliance, a statement about reduced formation and a statement about the absence of an unacceptable risk are not interchangeable. Each needs an identifiable scope and supporting material.
Inhance’s January 2025 update says process improvements reduced unintended PFAS formation by more than 90 percent. That is a company statement, not an independently reproduced result in this article. A reader assessing it would need the baseline, relevant substances, sampling period and production conditions. [2]
Make the chronology legible
A public account should show when a concern was identified, when a process was changed and when the new condition was tested. A report on an earlier sample should not be silently used to characterize every later article. Equally, announcing an improvement does not remove the historical finding from the record.
That chronology matters for leadership questions. A corporate biography can establish a tenure, but it cannot identify who approved every operating decision. Questions about particular decisions should be tied to records showing the date, responsibility and information available at the time.
Explain the audience for each assurance
A customer choosing a package needs evidence relevant to the intended product and use. A regulator may be evaluating a different legal or scientific question. A public-facing summary should explain those distinctions instead of presenting one statement as a universal answer.
For example, a report on extracted container-wall material does not automatically describe exposure from a finished product. The company could make its position easier to assess by identifying the measurement being discussed and the application to which it applies. EPA’s packaging materials show why that distinction is important. [3]
State what can be shared and what remains disputed
The disclosure litigation makes access to supporting records part of the public-interest story. A responsible response could identify the categories claimed as confidential and explain what useful, non-confidential information is available. The March 2026 opinion addressed completion of the administrative record; it should not be presented as a final judgment resolving every disclosure claim. [4]
These are proposed transparency questions, not a finding that Iyer concealed a particular hazard. No direct interview was conducted for this article. The aim is to move from personal insinuation toward documents and explanations that can be checked, corrected and compared over time.
Sources and further reading
- Aurora Capital Partners, Prakash Iyer corporate biography
- Inhance Technologies, regulatory update on fluorinated packaging, January 31, 2025
- EPA, PFAS in pesticide and other packaging
- District-court memorandum opinion, March 2, 2026, consolidated disclosure litigation, Document 60
This article distinguishes agency findings, company positions, pleadings and court holdings. It reports no newly verified individual disease case attributable to Inhance Technologies or Prakash Iyer. No direct interview, medical testing or independent reproduction of laboratory data was conducted for this edition.
